MARKET

ICCC

ICCC

Immucell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.20
+0.08
+0.94%
Closed 16:00 05/20 EDT
OPEN
8.11
PREV CLOSE
8.12
HIGH
8.47
LOW
8.11
VOLUME
2.44K
TURNOVER
19.28K
52 WEEK HIGH
10.96
52 WEEK LOW
7.30
MARKET CAP
63.49M
P/E (TTM)
58.11
1D
5D
1M
3M
1Y
5Y
ImmuCell's (NASDAQ:ICCC) investors will be pleased with their respectable 35% return over the last five years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...
Simply Wall St. · 4d ago
ImmuCell Q1 EPS $0.09 Up From $(0.06) YoY, Sales $6.00M Beat $5.40M Estimate
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.09 per share. This is a 250 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $6.00
Benzinga · 05/12 20:59
ImmuCell reports Q1 results
ImmuCell press release (NASDAQ:ICCC): Q1 GAAP EPS of $0.09. Revenue of $6M (+46.3% Y/Y). Cash and cash equivalents increased to $11.8 million as of March 31, 2022 from $10.2 million
Seekingalpha · 05/12 20:11
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ETPORTLAND, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets sci...
GlobeNewswire · 05/10 14:00
UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs. ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactur...
GlobeNewswire · 05/05 17:18
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the healt...
GlobeNewswire · 05/05 15:17
60 Biggest Movers From Yesterday
Gainers
Benzinga · 04/26 08:58
ImmuCell reports 46% growth in first quarter revenue estimate
ImmuCell (NASDAQ:ICCC) released its first quarter estimates on Monday with revenue up 46% Y/Y to $6M due to supply ease and higher production capacity. The company's CEO Michael F. Brigham told,
Seekingalpha · 04/11 20:40
More
No Data
Learn about the latest financial forecast of ICCC. Analyze the recent business situations of Immucell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ICCC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
High14.00
Average14.00
Low14.00
Current 8.20
EPS
Actual
Estimate
-0.030.010.040.08
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 38
Institutional Holdings: 1.33M
% Owned: 17.22%
Shares Outstanding: 7.74M
TypeInstitutionsShares
Increased
5
32.05K
New
4
60.70K
Decreased
9
29.51K
Sold Out
2
1.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/Director
David Tomsche
President/Chief Executive Officer/Treasurer/Secretary/Director
Michael Brigham
Vice President/Director of Sales/Director of Marketing/Director
Bobbi Brockmann
Vice President
Elizabeth Williams
Independent Director
Gloria Basse
Independent Director
David Cunningham
Independent Director
Steven Rosgen
Independent Director
Jonathan Rothschild
Independent Director
Paul Wainman
No Data
No Data
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.